Weight Loss Peptides: GLP-1 Agonists & Research Compounds
The weight loss peptide category contains the most clinically validated compounds in the entire peptide space. FDA-approved GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have demonstrated sustained weight reduction of 15–25% in large randomized controlled trials.
Unlike most peptide categories where evidence is preclinical or preliminary, weight loss peptides are backed by tens of thousands of patient-years of Phase 3 data. Semaglutide reduced mean body weight by ~15% in the STEP trials. Tirzepatide, a dual GIP/GLP-1 agonist, reduced body weight by ~21% in SURMOUNT-1. Retatrutide, a triple agonist in Phase 3, has shown ~24% reduction at 48 weeks. Beyond weight loss, GLP-1 agonists have demonstrated cardiovascular mortality reduction (SELECT trial) and potential benefits in kidney disease, sleep apnea, and addiction. This is the single best-validated therapeutic category in peptide medicine — but it also carries real side effects (GI intolerance in 20–40% of users, rare pancreatitis, muscle loss without resistance training) and is far from a "free lunch."
4 compounds in this category
Key Takeaways
- Semaglutide and tirzepatide are FDA-approved and backed by large Phase 3 trials
- Retatrutide (triple agonist) is in Phase 3 and shows the strongest weight loss data to date
- Cardiovascular benefits have been demonstrated, not just weight loss
- GI side effects affect 20–40% of users and drive most discontinuations
- Muscle loss is a real concern; resistance training should accompany all GLP-1 therapy
Compounds in This Category
SemaglutideOzempic, Wegovy
An FDA-approved GLP-1 receptor agonist used for type 2 diabetes and chronic weight management.
TirzepatideMounjaro, Zepbound
An FDA-approved dual GIP/GLP-1 receptor agonist that has shown the highest weight loss results of any approved medication.
AOD-9604Advanced Obesity Drug 9604, Anti-Obesity Drug 9604
A modified fragment of human growth hormone studied for fat metabolism without the growth-promoting effects of full GH.
RetatrutideLY3437943, Triple Agonist
A triple-acting GIP/GLP-1/glucagon receptor agonist in Phase 3 trials showing potentially the highest weight loss of any drug in development.
Frequently Asked Questions
Which weight loss peptide has the best evidence?
Tirzepatide currently leads with ~21% mean weight loss in SURMOUNT-1, surpassing semaglutide's ~15% in STEP. Retatrutide may exceed both when Phase 3 completes in 2026.
Are there non-GLP-1 weight loss peptides worth considering?
AOD-9604, CJC-1295, and MOTS-c have been marketed for weight loss but have weak or absent evidence compared to GLP-1 agonists. None are FDA-approved for weight management.
How much do GLP-1 peptides cost?
Brand-name Wegovy and Zepbound run $1,000–$1,400/month without insurance. Compounded semaglutide through 503A pharmacies typically costs $250–$500/month.
Can you lose weight permanently with peptides?
Most studies show substantial weight regain within 1 year of discontinuation. Long-term weight maintenance generally requires continued therapy or sustained lifestyle changes initiated during treatment.
What happens if I stop taking a GLP-1 agonist?
Appetite suppression reverses within days to weeks. Without behavioral changes, 60–70% of lost weight typically returns within 12 months, according to extension studies.